Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

Bibliographic Details
Main Authors:	William L Redmond, Annah S Rolig, Daniel C Rose, Saul Kivimae, Werner Rubas, Grace Helen McGee
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/4/e004218.full

Similar Items

451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
by: William Redmond, et al.
Published: (2020-11-01)

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
by: Anh Nguyen, et al.
Published: (2020-11-01)

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
by: Deborah Charych, et al.
Published: (2017-01-01)

A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells
by: Katherine E. Harris, et al.
Published: (2021-05-01)

Agonistic anti-CD40 enhances the CD8+ T cell response during vesicular stomatitis virus infection.
by: Julianne M Zickovich, et al.
Published: (2014-01-01)

Empty conformers of HLA-B preferentially bind CD8 and regulate CD8+ T cell function
by: Jie Geng, et al.
Published: (2018-05-01)

Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer
by: Katsuhito Teramatsu, et al.
Published: (2022-11-01)

Four types of Ca2+ signals in naive CD8+ cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists.
by: Bachmann, M, et al.
Published: (1997)

1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
by: William L Redmond, et al.
Published: (2023-11-01)

Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma
by: Mohadeseh Hasanpourghadi, et al.
Published: (2023-12-01)

CD8+CD122+ T-cells: a newly emerging regulator with central memory cell phenotypes
by: Dacan eChen, et al.
Published: (2015-10-01)

Resveratrol exerts antitumor effects by downregulating CD8+CD122+ Tregs in murine hepatocellular carcinoma
by: Qunfang Zhang, et al.
Published: (2020-01-01)

CD8+CD122+ T cell homeostasis is controlled by different levels of IL-15 trans-presentation
by: Gilbert Aaron Lee, et al.
Published: (2021-06-01)

Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56brightCD16− subset
by: Enrico Maggi, et al.
Published: (2022-01-01)

Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B.
by: Deborah A Lewinsohn, et al.
Published: (2007-09-01)

Agonistic CD40 Antibodies in Cancer Treatment
by: Dijana Djureinovic, et al.
Published: (2021-03-01)

CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling
by: Ben-Shun Hu, et al.
Published: (2020-10-01)

Correction: Toll-like reReceptor 8 agonists improve NK-cell function primarily targeting CD56brightCD16− subset
Published: (2022-03-01)

Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity
by: Saikat Manna, et al.
Published: (2020-10-01)

CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival
by: Huazhen Liu, et al.
Published: (2019-02-01)

Concepts for agonistic targeting of CD40 in immuno-oncology
by: David M. Richards, et al.
Published: (2020-02-01)

841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells
by: Tingting Li, et al.
Published: (2023-11-01)

Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth
by: Stéphanie Lacotte, et al.
Published: (2023-12-01)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
by: Arantza Azpilikueta, et al.
Published: (2022-03-01)

CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists.
by: Joselín Hernández-Ruiz, et al.
Published: (2010-01-01)

Dissection of agonistic and blocking effects of CD200 receptor antibodies
by: Akkaya, M, et al.
Published: (2013)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
by: Ran Salomon, et al.
Published: (2022-07-01)

Dissection of agonistic and blocking effects of CD200 receptor antibodies.
by: Munir Akkaya, et al.
Published: (2013-01-01)

Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors
by: Julien Schmidt, et al.
Published: (2023-06-01)

Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells
by: Kawaljit Kaur, et al.
Published: (2020-11-01)

Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Published: (2023-06-01)

The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies.
by: Zofia Pilch, et al.
Published: (2019-01-01)

GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory
by: Nick M. Durham, et al.
Published: (2017-06-01)

Higher Expression of Activated CD8+ T Lymphocytes (CD8+CD25+, CD8+CD69+ and CD8+CD95+) Mediate Early Post-Transplant Acute Tubular Injury in Kidney Recipients
by: Francisco Boix, et al.
Published: (2023-06-01)

769 A single dose of intratumoral TransCon™ TLR7/8 agonist monotherapy promoted sustained activation of antigen presenting cells resulting in CD4+ and CD8+ T cell activation and tumor growth inhibition
by: Amer Mirza, et al.
Published: (2021-11-01)

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
by: Sandra P. D’Angelo, et al.
Published: (2022-06-01)

Development of a novel TLR8 agonist for cancer immunotherapy
by: Yuxun Wang, et al.
Published: (2020-09-01)

Transmembrane protein CD69 acts as an S1PR1 agonist
by: Hongwen Chen, et al.
Published: (2023-04-01)

A New Immunosuppressive Molecule Emodin Induces both CD4+FoxP3+ and CD8+CD122+ Regulatory T Cells and Suppresses Murine Allograft Rejection
by: Feifei Qiu, et al.
Published: (2017-11-01)

Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency.
by: Steffen S Docken, et al.
Published: (2023-11-01)